Summary & Overview
HCPCS Q9989: Ustekinumab, Intravenous Injection, 1 mg
HCPCS Level II code Q9989 identifies ustekinumab in a 1 mg unit formulation for intravenous injection. As a biologic therapeutic coded at the drug unit level, this HCPCS code matters nationally because it aligns drug acquisition, billing, and reimbursement for hospital outpatient departments, infusion centers, and clinics that administer intravenous biologic therapy. Clear coding for unit-based biologics supports uniform claims processing and informs payment policy and utilization tracking for high-cost specialty medications.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare. Readers will find a concise explanation of the code’s clinical context and service settings, plus what to expect from payer coverage and benchmarking sections. The publication outlines typical billing scenarios for unit-dosed intravenous ustekinumab, summarizes policy considerations affecting drug administration sites, and highlights where readers can find related code groupings and reimbursement references.
This summary serves clinicians, billing professionals, and policy analysts seeking a national perspective on how a unit-based HCPCS Level II drug code for intravenous ustekinumab is used in claims and administrative workflows.
Billing Code Overview
HCPCS Level II code Q9989 denotes ustekinumab, for intravenous injection, 1 mg. This code represents the drug product and dosing unit for intravenous administration of ustekinumab, a monoclonal antibody used in certain immune-mediated conditions.
Service type: Intravenous infusion of a biologic agent
Typical site of service: Hospital outpatient department, infusion center, or clinic capable of intravenous biologic administration
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient with moderate-to-severe plaque psoriasis or Crohn disease presents to an infusion center for administration of an intravenous biologic formulation. The patient is evaluated by a registered nurse and an infusion center clinician for vitals, allergy review, and verification of identity and consent. The provider verifies the order for Q9989 (ustekinumab, IV, 1 mg) and calculates the required dose based on the manufacturer's weight-based intravenous induction dosing (typically given as a single IV infusion at week 0 for most indications). The nurse prepares the intravenous infusion using aseptic technique, administers per protocol over the recommended infusion time while monitoring for infusion reactions, documents lot number and administration details in the medical record, and schedules any required subcutaneous maintenance doses. Typical sites of service include hospital outpatient infusion centers, physician office infusion suites, and specialty infusion centers. Common clinical workflow elements include pre-infusion screening, medication preparation and verification, IV administration and monitoring, post-infusion documentation, and scheduling of follow-up and maintenance therapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the day of a procedure | Use when a distinct E/M visit is performed on the same day as an infusion and meets documentation requirements |